Navigation Links
Bioheart, Inc. Announces Additional Funding Support
Date:8/21/2008

E mark approval for marketing throughout Europe.

-- On July 10, 2008 the Company announced that it secured worldwide non-exclusive distribution rights to the Bioheart 3370 Heart Failure Monitor, an interactive and simple-to-use at-home intelligent device designed specifically to improve available healthcare to patients outside hospitals who are suffering from heart failure. The device, manufactured by RTX Healthcare A/S (Denmark), has 510(k) market clearance from the U.S. Food and Drug Administration for marketing in the U.S. and CE mark approval for marketing in Europe and other countries that follow this mark.

About Bioheart, Inc.:

Bioheart, Inc. (Nasdaq: BHRT) is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Bioheart, Inc. to Present at Red Chip Investor Conference in New York
2. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
3. Bioheart, Inc. Announces Financial Results for Second Quarter 2008
4. Bioheart, Inc. Announces Results of Annual Meeting
5. Bioheart, Inc., Announces Management Change
6. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
7. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
8. Bioheart, Inc., Added to Russell Microcap Index
9. Bioheart, Inc. to Transfer to Nasdaq Capital Market
10. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
11. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Center for Business Intelligence (CBI), a division ... the full agenda for the 6th ... The forum will take place at the ... Over 1,500 senior-level Finance, Accounting, Audit and ... since its inception, and this year,s meeting ...
(Date:12/15/2009)... - 45 Patients Enrolled ... Cells to Restore Cardiac Function ,, ... company specialising,in cell-based therapies for the treatment of ... months ahead of schedule,enrolment in the first stage ... a,unique stem cell therapy for heart failure. Forty-five ...
(Date:12/14/2009)... -- Vermillion, Inc. (Pink Sheets: VRML), a ... Wallen, Ph.D. Chief Scientific Officer, Senior Vice ... will be joining its board of directors ... ,, "Bill brings more than 20 years ... biotechnology," said Gail Page, Vermillion Executive Chairperson. ...
(Date:12/14/2009)... ROCKAWAY, N.J., Dec. 14 The third ... Approach , published by the ... FDA-approved treatment for anthracycline extravasation.(1) Anthracyclines are ... idarubicin and epirubicin that have been used in ... the early 1970s.(2) ,, According to ...
Breaking Biology Technology:CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5
... for clients who , require either EST or full ... features that allow us to provide industry-leading sequence quality , ... pipeline , ... Patented SPRI technology , ...
... , RNAPrep is a SPRI ... extracting and purifying total RNA from, Eukaryotic cultured ... procedure for isolating total RNA for use in applications such as microarray , ... format is scalable and consistently delivers high yield recovery ...
... , href="http://www.ambion.com/catalog/CatNum.php?1632"> Silencer , ... they can , be readily adapted for ... can be used for this application. See "<A , ... Cells " for experimintal data using dsRNA , ...
Other Biology Technology:cDNA Sequencing & Finishing 2RNAPrep - Total RNA Isolation Purification 2RNAPrep - Total RNA Isolation Purification 3Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 2Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 3Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 4
(Date:12/15/2009)... 2006, a team of Spanish and American researchers found the ... Bonares, Huelva. Now they have published, for the first time, ... with the death of the young cetacean, possibly a baleen ... first discovery of the partial fossil remains of a whale ... Huelva Sands sedimentary formation, but it is the first time ...
(Date:12/15/2009)... look forward to ultra-low powered or self powered ... phones. This is made possible with power management ... elements for power optimisation and higher energy efficiency ... design is the key enabling capability for power ... in advanced analog and mixed signal design capabilities, ...
(Date:12/15/2009)... a standard laboratory model organism, but there are ... analyze blood and blood-forming tissues in this species. ... easy-to-use laboratory resources from Cold Spring Harbor Laboratory ... features step-by-step protocols for the preparation, enumeration, ... and other hematopoietic tissues in the mouse. ...
Breaking Biology News(10 mins):Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3New source of classical techniques for blood-based studies in the laboratory mouse 2Pennsylvania DEP Lehigh Valley Berks County Air Quality Partnership Urge Public Transit Use 50648 1Pennsylvania DEP Lehigh Valley Berks County Air Quality Partnership Urge Public Transit Use 50648 2Nephros Receives 510k Approval for Dual Stage Ultrafilters 50646 1Nephros Receives 510k Approval for Dual Stage Ultrafilters 50646 2Nephros Receives 510k Approval for Dual Stage Ultrafilters 50646 3Predicting the return of prostate cancer 3A New Johns Hopkins study betters the odds of success 50643 1Predicting the return of prostate cancer 3A New Johns Hopkins study betters the odds of success 50643 2
... Sept. 4, 2008 Declaring the success of an ... Eli and Edythe Broad announced today that they have ... Harvard and MIT to $600 million. Adding to their ... an endowment of $400 million to convert the Institute, ...
... and New South Wales have put aside their competitive ... project, as announced by Innovation Minister Gavin Jennings and ... today. , Scientists from the Monash Institute of ... will compare two different methods of creating patient-specific stem ...
... University of Texas Medical Branch at Galveston researchers have discovered ... Ebola Zaire virus infects cells a critical step to ... the virus. , Ebola produces severe and often fatal hemorrhagic ... 90 percent in some outbreaks. No vaccine or antiviral therapy ...
Other Biology News:Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT 2Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT 3Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT 4Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT 5Stem cell research puts interstate rivalry on hold 2Scientists uncover Ebola cell-invasion strategy 2
... Double staining is a technique used ... single tissue.(1-6) PicTure™-Double Staining Kit is a ... detecting two antigens simultaneously in the same ... sensitivity. The antigens can be identified using ...
... a fully automated microplate based multi-detection ... in academia and industry. The FLUOstar ... Fluorescence Intensity including FRET and ... including DELFIATM High-Performance Luminescence (flash ...
... The Digital Clamp One can operate as ... as a Conductance (Dynamic) Clamp in electrophysiology research ... good as conventional analog equipment. • ... by very recent advances in the capabilities of ...
... Analysis Note: Agglutination activity is expressed in ... dilutions in phosphate buffered saline, pH 6.8, of ... This activity is the lowest concentration to agglutinate ... erythrocytes after 1 hour incubation at 25 C. ...
Biology Products: